Explore
Validate
Learn
Western blot
Other assayAntibody data
- Antibody Data
- Antigen structure
- References [1]
- Comments [0]
- Validations
- Other assay [2]
Submit
Validation data
Reference
Comment
Report error
- Product number
- PA5-46125 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- CCDC66 Polyclonal Antibody
- Antibody type
- Polyclonal
- Antigen
- Synthetic peptide
- Description
- Peptide sequence: PLRTKTGHIL KSTQDTCIGS EKLLQKKPVG SETSQAKGEK NGMTFSSTKD Sequence homology: Cow: 79%; Dog: 79%; Horse: 79%; Human: 100%
- Reactivity
- Human
- Host
- Rabbit
- Isotype
- IgG
- Vial size
- 100 µL
- Concentration
- 0.5 mg/mL
- Storage
- -20° C, Avoid Freeze/Thaw Cycles
Submitted references Circular RNA CCDC66 facilitates abdominal aortic aneurysm through the overexpression of CCDC66.
Yang R, Wang Z, Meng G, Hua L
Cell biochemistry and function 2020 Oct;38(7):830-838
Cell biochemistry and function 2020 Oct;38(7):830-838
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Circular RNA CCDC66 (circCCDC66) modulated vascular smooth muscle cell (VSMC) growth via regulating its host gene. A, qRT-PCR analysis of CCDC66 mRNA in VSMCs transfected with sh/ctrl, sh/circCCDC66#1 or sh/circCCDC66#2. B, qRT-PCR analysis of CCDC66 mRNA and circCCDC66 in VSMCs transfected with NC or circCCDC66. C, VSMCs were transfected with sh/ctrl, sh/circCCDC66#1, sh/circCCDC66#2, NC, circCCDC66 overexpressing plasmids; CCDC66 protein was detected in western blot. D, Knockdown efficiency of CCDC66 in qRT-PCR and western blot. E, VSMCs were transfected with sh/ctrl, sh/CCDC66#1 or sh/CCDC66#2; CCK-8 examined VSMC viability. F, EdU examined the proliferation of VSMC under indicated treatments. G and H, TUNEL and JC-1 staining monitored the loss of VSMCs under different treatments. ** P < .01
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Circular RNA CCDC66 (circCCDC66) targeted miR-342-3p to upregulate its host gene. A, Luciferase reporter assay was designed for interrogating the impacts of circCCDC66 on CCDC66 promoter. B and C, CircCCDC66 distribution in vascular smooth muscle cells (VSMCs) from the analyses of subcellular fractionation and FISH assays. D, RNA pull-down using biotinylated miRNAs to precipitate circCCDC66. E, Bindings sites among circCCDC66, CCDC66 and miR-342-3p. F, Luciferase activity of circCCDC66 in VSMCs and HEK293T cells transfected with miR-342-3p mimics. G, Luciferase activity of CCDC66 in VSMCs and HEK293T cells transfected with miR-342-3p mimics. H, CircCCDC66, CCDC66 and miR-342-3p were enriched in Ago2 group. I, qRT-PCR and western blot of CCDC66 expression in VSMCs transfected with sh/circCCDC66#1 alone or co-transfected with miR-342-3p inhibitor. ** P < .01
